« Time Magazine's graffiti billboard in SoHo |
| IBM pockets $775 million from Microsoft »
July 01, 2005
Pfizer goes 0-2 with new drugs in development
If you're going to release bad news, do it when nobody's watching. That's what Pfizer must be thinking by releasing news that it is halting development of two promising drugs (one for HIV, one for smoker's lung and asthma) on the Friday before the 4th of July weekend. Maybe all the Wall Street traders will be busy thinking about the Hamptons and will forget about Pfizer when they get back to work on the 5th.
Anyway, Reuters is reporting that Pfizer is dropping the HIV drug capravirine based on the results of two mid-stage trials. In addition, the company is shutting down its development of Daxas (touted as a potential blockbuster) for the treatment of chronic obstructive pulmonary disease.
+ TrackBacks (0) | Category: Biotech
- RELATED ENTRIES
- East Village bar up for sale on eBay
- Eliot Spitzer takes on the national cinema chains
- California winemakers to sell wine to New Yorkers via the Internet
- A blogger could become "Media Person of the Year"
- A la carte cable TV pricing
- NYSIA Incubator launch party tonight
- Why the mathematics of congestion pricing don't work
- Enjoy the holiday shopping bargains at Century 21 while you can